Table 1.
Overview of T-cell and NK-cell redirected therapeutics in clinical trials *.
| Type | Clinical Stage | Total | ||
|---|---|---|---|---|
| Phase I/II | Phase III | Approved | ||
| T-cell or NK cell-redirecting bispecific Abs | 59 | 0 | 2 ** | 61 |
| Autologous CAR-T, CAR-NK, CAR-NKT cells | 207 | 2 | 2 | 211 |
| Allogeneic CAR-T, CAR-NK, CAR-NKT cells | 14 | 0 | 0 | 14 |
| Allogeneic NK or Autologous T cells engineered with Fc RIIIa for binding therapeutic antibodies | 3 | 0 | 0 | 3 |
| Total of CAR-T, T-cell or NK cell redirected killing of tumor cells | 283 | 2 | 4 | 289 |
* BiStro Biotech Consulting LLC database, locked 20 June 2019. Data obtained from Clinicaltrials.gov, literature papers, company websites, analyst reports and other sources. ** One of these, Removab®, was voluntarily discontinued in 2017 by the sponsor.